SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: William Strop who wrote (286)7/6/1997 5:30:00 PM
From: William Strop   of 1972
 
All,

I talked to Alan Engbring of Investor Relations at Vical (619) 453-9900 on Friday, June 27, 1997. I had questions regarding the Scientific American, June/1997 article about Genetic Therapy. I am currently organizing my thoughts re: that topic and will post them when finished, but for now, here are some other points (most, if not all are old news) covered in the conversation.

Vical - progress during the first half of 1997:

1. Patents for Naked DNA delivery (this gives further exposure to the technology and more name recognition to Vical.

2. Influenza vaccine Phase I clinical completed but no results reported yet.

3. Talks with potential partners re: using the Vical technology continuing.

4. Allovectin-7 Phase I/II clinical results showing promise against Melanoma.

Vical - `expected' progress during the second half of 1997:

1. Get more test results re: Allovectin-7 use on Melanoma.

2. Announce potential partners who may use Vical's technology.

3. Hope to have Phase I clinical results re: influenza vaccine announced (if positive, this would be a further validation of the Naked DNA technology).

4. Start their own malaria vaccine Phase I clinical.

5. Keep moving Allovectin-7 toward product category.

Like I said, probably old information that is available in the annual report and press releases...

Bill
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News